Patrys Ltd (ASX: PAB) Share Price and News
Price
$0.001
Movement
0.00 (0.0)
as at 24 Jun - Closed (20 mins delayed)
52 Week Range
$0.001 - $0.008
1 Year Return
-85.71%
Patrys Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$0.001
Day Change
0.00 (0.0)
52 Week Range
$0.001 - $0.008
Yesterday's Close
$0.001
Today's Open
$0.001
Days Range
$0.001 - $0.001
Volume
171,160
Avg. Volume (1 month)
3,044,715
Turnover
$171
as at 24 Jun - Closed
Patrys Ltd (ASX: PAB)
Latest News

Healthcare Shares
Here's why the Patrys (ASX:PAB) share price is tumbling 16% today

Share Market News
Here's why the Patrys (ASX: PAB) share price is climbing 13% today

Ask a Fund Manager
Why we avoid mining and biotech ASX shares: fund manager
PAB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
23rd Jun 2025 2025-06-23T16:48:53 | Notification of cessation of securities - PAB | YesNo | 4:48pm | 4 | 13k |
23rd Jun 2025 2025-06-23T16:47:28 | Final Director's Interest Notices x2 | YesNo | 4:47pm | 4 | 788k |
23rd Jun 2025 2025-06-23T16:43:38 | Initial Director's Interest Notices x2 | YesNo | 4:43pm | 4 | 617k |
18th Jun 2025 2025-06-18T09:40:07 | Section 708A Cleansing Statement | YesNo | 9:40am | 2 | 275k |
18th Jun 2025 2025-06-18T09:29:02 | Application for quotation of securities - PAB | YesNo | 9:29am | 6 | 16k |
17th Jun 2025 2025-06-17T09:35:34 | Proposed issue of securities - PAB | YesNo | 9:35am | 5 | 16k |
17th Jun 2025 2025-06-17T09:32:34 | Deed of Release entered into with CEO | YesNo | 9:32am | 1 | 219k |
10th Jun 2025 2025-06-10T17:47:00 | Reinstatement to Official Quotation | YesNo | 5:47pm | 1 | 104k |
10th Jun 2025 2025-06-10T17:46:50 | Proposed issue of securities - PAB | YesNo | 5:46pm | 6 | 19k |
10th Jun 2025 2025-06-10T17:46:44 | Proposed issue of securities - PAB | YesNo | 5:46pm | 6 | 20k |
About Patrys Ltd
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.
PAB Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 Jun 2025 | $0.00 | $0.00 | 0.00% | 863,380 | $0.00 | $0.00 | $0.00 |
20 Jun 2025 | $0.00 | $0.00 | 0.00% | 2,318,106 | $0.00 | $0.00 | $0.00 |
19 Jun 2025 | $0.00 | $0.00 | 0.00% | 1,575,000 | $0.00 | $0.00 | $0.00 |
18 Jun 2025 | $0.00 | $0.00 | 0.00% | 1,288,770 | $0.00 | $0.00 | $0.00 |
17 Jun 2025 | $0.00 | $0.00 | 0.00% | 1,580,000 | $0.00 | $0.00 | $0.00 |
16 Jun 2025 | $0.00 | $0.00 | 0.00% | 380,326 | $0.00 | $0.00 | $0.00 |
13 Jun 2025 | $0.00 | $0.00 | 0.00% | 2,748,021 | $0.00 | $0.00 | $0.00 |
12 Jun 2025 | $0.00 | $0.00 | 0.00% | 2,591,022 | $0.00 | $0.00 | $0.00 |
11 Jun 2025 | $0.00 | $0.00 | 0.00% | 43,052,603 | $0.00 | $0.00 | $0.00 |
29 May 2025 | $0.00 | $0.00 | 0.00% | 2,500,000 | $0.00 | $0.00 | $0.00 |
28 May 2025 | $0.00 | $0.00 | 0.00% | 1,750,000 | $0.00 | $0.00 | $0.00 |
27 May 2025 | $0.00 | $0.00 | 0.00% | 247,068 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
18 Dec 2024 | James Campbell | Expiry | 11,000,000 | $44,000 |
Options expired.
|
18 Dec 2024 | Michael Stork | Expiry | 800,000 | $3,200 |
Options expired.
|
18 Dec 2024 | Pamela Klein | Expiry | 800,000 | $3,200 |
Options expired. As per announcement on 24-12-2024
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr James Campbell | Chief Executive OfficerManaging Director | Nov 2014 |
Dr. Campbell has over 30 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of Australian and international biotechnology companies. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX: CXS), where, as a member of the executive team he helped transform a research based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr Campbell chairs the board of Australia's peak industry body for biotechnology, AusBiotech.
|
Mr Peter James Christie | Non-Executive ChairmanNon-Executive Director | Jun 2025 |
Mr Christie has served on the boards of several public companies in the resource sector since 2006 and has developed interests in hospitality and property development.
Mr. Christie is the Director of Hawkins Christie Management Services, a firm based in Nedlands, Western Australia, providing accounting and management services. He is also the current President of the South Fremantle Football Club, a role he has held since 2018, following over a decade of service on the club's board. His leadership has been instrumental in the club's strategic growth and community engagement initiatives. |
Dr Anton Uvarov | Non-Executive Director | Jun 2025 |
Dr. Anton Uvarov has experience in the healthcare sector, with a particular focus on
neuroscience. He began his career in biotechnology investment as an equities analyst at Citigroup and has since co-founded and served as a director of several ASX-listed companies, including clinical-stage ventures such as Dimerix (ASX:DXB) and Actinogen Medical (ASX:ACW). Dr. Uvarov is currently a Non-Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), and previously served on the board of Imugene (ASX:IMU), a late-stage clinical oncology company. Dr. Uvarov is also the Executive Director and co-founder of BlinkLab (ASX:BB1), a digital diagnostics company focused on autism. |
Mr Stefan Ross | Company Secretary | Oct 2021 |
Mr Ross has over 10 years of experience in accounting and secretarial services for ASX listed companies. His experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, and board and secretarial support.
|
Rebecca Tunstall | Vice President Corporate Development |
-
|
|
Valentina Dubljevic | Vice President Research & Development |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Dr Dax Marcus Calder | 129,000,000 | 6.27% |
Citicorp Nominees Pty Limited | 99,195,175 | 4.82% |
Stork Holdings 2010 Ltd | 98,773,814 | 4.80% |
Dax Calder Pty Ltd | 65,000,000 | 3.16% |
Mr Mladen Marusic | 59,680,843 | 2.90% |
Kemast Investments Pty Ltd <Km Stokes S/F No 1 A/C> | 39,814,272 | 1.94% |
Estelleanne Pty Ltd | 35,500,000 | 1.73% |
Marginata Pty Ltd <Roy Bolton Super Fund A/C> | 31,000,000 | 1.51% |
Altum Trustees Limited <Mk Pension Plan-473278 A/C> | 28,049,888 | 1.36% |
Staffwear Pty Ltd <Dax Calder Super Fund A/C> | 27,000,000 | 1.31% |
Altum Trustees Ltd <The Konda Family A/C> | 26,499,994 | 1.29% |
Towns Corporation Pty Ltd <PAE Family A/C> | 21,715,000 | 1.06% |
Mr Vinh Tran | 21,513,277 | 1.05% |
Mr Justin Frank Puddick | 19,000,000 | 0.92% |
Yale University | 16,116,324 | 0.78% |
Edstop Pty Limited <Superannuation Fund A/C> | 15,501,223 | 0.75% |
Mr Craig Geoffrey Thomas | 13,439,814 | 0.65% |
Mr Benjamin John Wagner | 13,280,000 | 0.65% |
Mr Vishal Gumber | 12,933,733 | 0.63% |
Mr Thomas Edgar Edmunds and Mrs Susan Rae Edmunds <The Edmunds Family S/F A/C> | 11,500,000 | 0.56% |